CN101180066A - 二核苷多磷酸衍生物的新应用 - Google Patents

二核苷多磷酸衍生物的新应用 Download PDF

Info

Publication number
CN101180066A
CN101180066A CNA2006800090694A CN200680009069A CN101180066A CN 101180066 A CN101180066 A CN 101180066A CN A2006800090694 A CNA2006800090694 A CN A2006800090694A CN 200680009069 A CN200680009069 A CN 200680009069A CN 101180066 A CN101180066 A CN 101180066A
Authority
CN
China
Prior art keywords
compound
formula
independently selected
ppa
appch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800090694A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·米勒
M·赖特
J·A·坦纳
N·洛佐瓦亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IC Vec Ltd
Original Assignee
IC Vec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IC Vec Ltd filed Critical IC Vec Ltd
Publication of CN101180066A publication Critical patent/CN101180066A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA2006800090694A 2005-02-03 2006-02-01 二核苷多磷酸衍生物的新应用 Pending CN101180066A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502250.4A GB0502250D0 (en) 2005-02-03 2005-02-03 Use
GB0502250.4 2005-02-03

Publications (1)

Publication Number Publication Date
CN101180066A true CN101180066A (zh) 2008-05-14

Family

ID=34307930

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800090694A Pending CN101180066A (zh) 2005-02-03 2006-02-01 二核苷多磷酸衍生物的新应用

Country Status (8)

Country Link
US (1) US20080319184A1 (https=)
EP (1) EP1846004A1 (https=)
JP (1) JP2008528665A (https=)
CN (1) CN101180066A (https=)
AU (1) AU2006210715A1 (https=)
CA (1) CA2596959A1 (https=)
GB (1) GB0502250D0 (https=)
WO (1) WO2006082397A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102773A (zh) * 2013-11-27 2016-11-09 全球橡果有限公司 组合物
CN106163561A (zh) * 2013-11-27 2016-11-23 全球橡果有限公司 组合物
CN109096346A (zh) * 2017-06-21 2018-12-28 株式会社钟根堂 制备二核苷多磷酸化合物的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
JP7707171B2 (ja) * 2019-12-20 2025-07-14 ヌバミッド エスエー 新規のニコチンアミドジヌクレオチド誘導体およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
DK0981534T3 (da) * 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
GB9711848D0 (en) * 1997-06-06 1997-08-06 William Harvey Research Limite Treatment and prophylaxis of infraction
WO1999003480A1 (en) * 1997-07-17 1999-01-28 William Harvey Research Limited Use of adenosine tri- or tetra-phosphates and their analogues for the treatment of cerebral infarction
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
WO2003000056A1 (en) * 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US7203743B2 (en) * 2001-12-28 2007-04-10 Nortel Networks Limited Hierarchical tree-based protection scheme for mesh networks

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102773A (zh) * 2013-11-27 2016-11-09 全球橡果有限公司 组合物
CN106163561A (zh) * 2013-11-27 2016-11-23 全球橡果有限公司 组合物
CN109096346A (zh) * 2017-06-21 2018-12-28 株式会社钟根堂 制备二核苷多磷酸化合物的方法
CN109096346B (zh) * 2017-06-21 2023-08-01 株式会社钟根堂 制备二核苷多磷酸化合物的方法

Also Published As

Publication number Publication date
GB0502250D0 (en) 2005-03-09
EP1846004A1 (en) 2007-10-24
WO2006082397A1 (en) 2006-08-10
CA2596959A1 (en) 2006-08-10
JP2008528665A (ja) 2008-07-31
AU2006210715A1 (en) 2006-08-10
US20080319184A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
Sperlágh et al. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects
Wang et al. Antidepressant-like effect of ginsenoside Rb1 on potentiating synaptic plasticity via the miR-134–mediated BDNF signaling pathway in a mouse model of chronic stress-induced depression
Fields et al. Purinergic signalling in neuron–glia interactions
Lee Neurotransmitters and microglial-mediated neuroinflammation
Burnstock Historical review: ATP as a neurotransmitter
Cui et al. Mdivi-1 protects against ischemic brain injury via elevating extracellular adenosine in a cAMP/CREB-CD39-dependent manner
Kennedy P2X receptors: targets for novel analgesics?
Xu A review on the chemical synthesis of pyrophosphate bonds in bioactive nucleoside diphosphate analogs
Irnich et al. ATP stimulates peripheral axons in human, rat and mouse—differential involvement of A2B adenosine and P2X purinergic receptors
AU2013264966A1 (en) Dinuceloside polyphosphates for the treatment of pain
WO2008113072A2 (en) Gpcr enhanced neuroprotection to treat brain injury
CN101180066A (zh) 二核苷多磷酸衍生物的新应用
Burnstock Purinergic signalling in development
Eliahu et al. A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold
Melnik et al. Diadenosine polyphosphate analog controls postsynaptic excitation in CA3-CA1 synapses via a nitric oxide-dependent mechanism
Manhães et al. The role of nucleotides in glial cells during peripheral nerve trauma and compressive disorders
CN118922429A (zh) 异常磷酸化和tau蛋白聚集的抑制剂
Verkhratsky et al. Adenosine triphosphate (ATP) as a neurotransmitter
Volonté et al. Purinergic signalling: what is missing and needed next? The use of transgenic mice, crystallographic analysis and MicroRNA
Cho et al. P2X and P2Y receptors mediate contraction induced by electrical field stimulation in feline esophageal smooth muscle
Zemková et al. Molecular structure of purinergic P2X receptors and their expression in the hypothalamus and pituitary
CN114984020B (zh) 腺苷酸环化酶抑制剂在制备用于治疗癫痫及其相关疾病的药物中的用途
Nakatsuka et al. ATP and its receptors in pain
Voevoda et al. Trace Amine-associated Receptor 1: Role in the Implementation of Neuroprotective Signaling Pathwaysays
Burnstock et al. Early history of purinergic signalling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080514